A phase II study with Tegafur/Uracil and Peg-Interferon after TACE for hepatocelluler carcinoma
Phase 2
- Conditions
- Advanced hepatocellular carcinoma
- Registration Number
- JPRN-C000000275
- Lead Sponsor
- The third department of Internal Medicine, Wakayama Medical University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 20
Inclusion Criteria
Not provided
Exclusion Criteria
1)Allergic reaction to IFN and/or UFT 2)Positive by prick test of IFN 3)Severe liver damage after TAE 4)Autoimmune disease 5)Depression or mental neuropathic illness 6)Uncontrolled heart or renal desease 7)Pregnant or nursing 8)Extensive leukopenia or extensive thrombocytopia 9)Use Sho-saiko-to 10)Other uncontrolled severe illness 11)Other inappropriate patient
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Response rate
- Secondary Outcome Measures
Name Time Method Safety profile